Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities

JMP Securities restated their market outperform rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $21.00 price target on the biotechnology company’s stock, down from their prior price target of $22.00.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. decreased their target price on Enanta Pharmaceuticals from $11.00 to $10.00 and set an “underweight” rating on the stock in a research report on Tuesday, August 6th. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of Enanta Pharmaceuticals in a report on Thursday, October 10th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $19.50.

Enanta Pharmaceuticals Trading Down 2.6 %

ENTA stock opened at $8.60 on Tuesday. The company has a market cap of $182.23 million, a price-to-earnings ratio of -1.57 and a beta of 0.56. The firm has a 50 day moving average of $10.81 and a 200-day moving average of $12.25. Enanta Pharmaceuticals has a 12-month low of $8.00 and a 12-month high of $17.80.

Institutional Trading of Enanta Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Enanta Pharmaceuticals by 7.5% in the 1st quarter. Vanguard Group Inc. now owns 1,928,078 shares of the biotechnology company’s stock valued at $33,664,000 after purchasing an additional 134,292 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Enanta Pharmaceuticals by 65.8% in the second quarter. Cubist Systematic Strategies LLC now owns 45,350 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 18,003 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Enanta Pharmaceuticals by 35.4% during the second quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 7,287 shares during the period. Rhumbline Advisers grew its stake in Enanta Pharmaceuticals by 4.7% in the 2nd quarter. Rhumbline Advisers now owns 34,566 shares of the biotechnology company’s stock worth $448,000 after acquiring an additional 1,548 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Enanta Pharmaceuticals by 13.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 73,841 shares of the biotechnology company’s stock valued at $958,000 after acquiring an additional 8,645 shares during the last quarter. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.